Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Bukirwa, Hasifa ^a   Unnikrishnan, B ^b   Kramer, Christine V ^c   Sinclair, David ^c   Nair, Suma ^d   Tharyan, Prathap ^e  

^a MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^b KASTURBA MEDICAL COLLEGE   (India)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d KASTURBA MEDICAL COLLEGE   (India)

^e CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE PLUS MEFLOQUINE; ARTESUNATE PLUS PYRONARIDINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHLOROQUINE; HEMOGLOBIN; PYRONARIDINE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; BENFLUMETOL; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; MEFLOQUINE; NAPHTHYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECG ABNORMALITY; FEVER; GAMETOCYTE; HEADACHE; HEMATURIA; HUMAN; HYPERTRANSAMINASEMIA; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LIVER TOXICITY; MALARIA FALCIPARUM; MULTICENTER STUDY (TOPIC); MYALGIA; PARASITE CLEARANCE; PARASITEMIA; PLATELET COUNT; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UPPER ABDOMINAL PAIN; VERTIGO; VOMITING; ADULT; CHILD; DRUG COMBINATION; DRUG EFFECT; LIVER; META ANALYSIS; METABOLISM; METHODOLOGY;

ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FLUORENES; HUMANS; LIVER; MALARIA, FALCIPARUM; MEFLOQUINE; NAPHTHYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907263642     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006404.pub2     Document Type: Review

References (81)

1. Kayentao K. Pyronaridine-artesunate versus artemether/lumefantrine: efficacy in malaria patients with uncomplicated acute falciparum malaria: results of a pivotal Phase III trial. American Journal of Tropical Medicine and Hygiene. 2008; Vol. 79 (6 Suppl):114.
2. Kayentao K, Doumbo OK, Pénali LK, Offianan AT, Bhatt KM, Kimani J, et al.Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malaria Journal 2012;11:364.
3. NCT00541385 . Pyronaridine artesunate 3:1 granule formulation vs. Coartem© crushed tablets in P. falciparum malaria pediatric patients. www.clinicaltrials.gov/show/NCT00541385 (accessed 30 November 2010).
4. Duparc S, Borghini-Fuhrer I, Craft JC, Arbe-Barnes S, Miller RM, Shin CS, et al.Efficacy of pyronaridine/artesunate in clinical trials in patients with uncomplicated acute Plasmodium falciparum or Plasmodium vivax malaria: results of an integrated analysis. American Journal of Tropical Medicine and Hygiene. 2009; Vol. 81 Suppl:51-100.
5. Duparc S, Borghini-Fuhrer I, Craft JC, Arbe-Barnes S, Miller RM, Shin CS, et al.Safety of pyronaridine/artesunate in clinical trials in patients with uncomplicated acute Plasmodium falciparum or Plasmodium vivax malaria: results of an integrated analysis. American Journal of Tropical Medicine and Hygiene. 2009; Vol. 81 Suppl:101-150.
6. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, et al.Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One 2011;6(1):e14501.
7. Ringwald P, Bickii J, Basco L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet 1996;347(8993):24-8.
8. Ringwald P, Bickii, Basco LK. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clinical Infectious Diseases 1998;26(4):946-53.
9. NCT00403260 . Pyronaridine artesunate (3:1) versus mefloquine artesunate in P. falciparum malaria patients. www.clinicaltrials.gov/show/NCT00403260.
10. Rueangweerayut R, Phyo AP, Uchaisin C, Poravuth Y, Quang Binh T, Tinto H, et al.A randomized clinical trial comparing the efficacy and safety of fixed-dose pyronaridine-artesunate versus mefloquine plus artesunate in uncomplicated Plasmodium falciparum malaria. Submitted under review; personal communication by email from Isabelle Borghini Fuhrer, Medicines for Malaria Venture.
11. Rueangweerayut R, Phyo AP, Uchaisin C, Socheat D, Quang Binh T, Tinto H, et al.Efficacy and safety of pyronaridine/artesunate fixed-dose combination compared with mefloquine plus artesunate in patients with acute uncomplicated Plasmodium falciparum malaria: results of a pivotal phase III trial. Tropical Medicine and International Health. 2009; Vol. 14 Suppl 2:30-97.
12. Rueangweerayut R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, et al.Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. New England Journal of Medicine 2012;366(14):1298-309.
13. Rueangweerayut R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, et al.Supplement to: Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. New England Journal of Medicine 2012;366(14):1298-309.
14. Duparc S, Borghini-Fuhrer I, Craft JC, Arbe-Barnes S, Miller RM, Shin CS, et al.Safety of pyronaridine/artesunate in clinical trials in patients with uncomplicated acute Plasmodium falciparum or Plasmodium vivax malaria: results of an integrated analysis. American Journal of Tropical Medicine and Hygiene. 2009; Vol. 81 Suppl:101-150.
15. Duparc S, Borghini-Fuhrer I, Craft JC, Arbe-Barnes S, Miller RM, Shin CS, et al.Efficacy of pyronaridine/artesunate in clinical trials in patients with uncomplicated acute Plasmodium falciparum or Plasmodium vivax malaria: results of an integrated analysis. American Journal of Tropical Medicine and Hygiene. 2009; Vol. 81 Suppl:51-100.
16. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, et al.Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010;375(9724):1457-67.
17. Cai X, Chen C, Zheng X, Wang X. Preliminary study of dihydroartemisinin for treatment of falciparum malaria. Journal of Practical Parasitic Diseases 1999;7(3):104-5.
18. Chang C, et al.Analysis on the results of antimalarial pyronaridine combined with sulfadoxine and pyrimethamine to falciparum malaria. Journal of Practical Parasitic Diseases 1997;5(3):104-7.
19. Che LG, Huang KG, Yang HL, Yu L, Lin ZL, Huang R. Combined use of pyronaridine, sulfadoxine and primaquine in areas with chloroquine-resistant falciparum malaria. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases] 1987;5(3):194-6. [: ISSN: 1000-7423]
20. Che L, Huang K, Ying D, Yang H, Yang P. Efficacy of two combined therapies for treatment of chloroquine-resistant falciparum malaria. Chinese Journal of Parasitic Disease Control 1990;3(1):24-6.
21. Chen L, Dai ZR, Qian YL, Ma ZM, Guo FC, Liao ZH, et al.Observation on the efficacy of combined use of some new antimalarials for the treatment of falciparum malaria in Hainan Province. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1989;7(2):81-4.
22. ®) for treatment of children with acute uncomplicated Plasmodium falciparum malaria. Tropical Medicine and International Health. 2007; Vol. 12 Suppl 1:222.
23. Huang ZS, Shao BR, Meng F, Zeng LH, Ye XY, Huang J, et al.Effects of combined dose of pyronaridine/sulfadoxine/pyrimethamine on falciparum malaria. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases] 1988;6(4):285-8.
24. Huang ZS, Feng Z, Meng F, Zeng LH, Lin X, Zhen Y, Xing QF, Guo RN. Therapeutic effect of pyronaridine in plain tablets and enteric coated tablets in falciparum malaria patients. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases] 1989;7(1):19-21.
25. Huang Z, Shao B, Meng F, Shi X. Comparison of different regimen of pyronaridine and sulfadoxine combined with pyrimethamine in the treatment of malignant malaria. Chinese Journal of Infectious Diseases 1993;11(Suppl 3):175-7. [: ISSN: CN-00256187]
26. Haung Z, Meng F, Fu S. Comparative studies on the treatment of drug-resistant falciparum malaria with single-dose or two-day regimens of pyronaridine/sulfadoxine-pyrimethamine plus primaquine. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases] 1996;14(4):314-7.
27. Liu DQ, Lin SG, Feng XP, Chen WJ, Chen PL, Wu HM, et al.Study on Treatment of Multi-drug resistant Falciparum Malaria by Using a Combination of Dihydroartemisinin and Pyronaridine. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi [Chinese Journal of Parasitology and Parasitic Diseases] 2002;20(4):193-6.
28. Looareesuwan S, Kyle DE, Viravan C, Vanijanonta S, Wilairatana P, Wernsdorfer WH. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. American Journal of Tropical Medicine and Hygiene 1996;54(2):205-9.
29. Looareesuwan S, Gaye O, Tjitra E, Bojang K, Socheat D, Piola P. Results of a randomized, multicentre, phase II, dose-ranging, clinical study to assess the safety and efficacy of fixed dose, orally administered pyronaridine and artesunate in adult patients with acute uncomplicated Plasmodium falciparum malaria. Abstracts of the 56th Annual Meeting of the American Society of Tropical Medicine and Hygiene. 2007:287.
30. NCT01156389 . Pyronaridine/Artesunate-Ritonavir drug drug interaction study. www.clinicaltrials.gov/show/ NCT01156389 (accessed 09 August 2010).
31. No authors listed. Efficacy of pyronaridine in 510 acute malaria cases. Zhonghua Nei Ke Za Zhi 1985;24(11):646-7, 700.
32. Pang X, Xing Q, Lin K, Li X, Ou F, Ou L, et al.Efficacy of combined use of various preparations of pyronaridine, sulfadoxine and pyrimethamine in the treatment of falciparum malaria. Chinese Journal of Parasitic Disease Control 1989;2(3):167-8.
33. Piola P, Fleckenstein L. Pharmacokinetics, clinical and safety outcomes of pyronaridine/artesunate treatment of acute Plasmodium falciparum malaria in Uganda. Abstracts of the 57th Annual meeting of the American Society of Tropical Medicine and Hygiene. Available at: www.astmh.org: American Society of Tropical Medicine and Hygiene, 2008:252.
34. Piola P, Fleckenstein L. Pharmacokinetics, clinical and safety outcomes of pyronaridine/artesunate treatment of acute Plasmodium falciparum malaria in Uganda. American Journal of Tropical Medicine and Hygiene. 2008; Vol. 79 Suppl:195.
35. Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp Iv, Bélard S, et al.Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. Journal of Infectious Diseases 2008;198(6):911-9.
36. Shao BR, Huang ZS, Shi XH, Meng F. A 5-year surveillance of sensitivity in vivo of Plasmodium falciparum to pyronaridine/sulfadoxine/pyrimethamine in Diaoluo area, Hainan Province. Southeast Asian Journal of Tropical Medicine and Public Health 1991;22(1):65-7.
37. Tan B, Fleckenstein lL, Yu KS, Jang IJ. Population pharmacokinetics of artesunate and dihydroartemisinin in healthy volunteers. American Journal of Tropical Medicine and Hygiene. 2008; Vol. 79 Suppl:100-49.
38. Wattanavijitkul T, Fleckenstein L, Yu KS, Jang IJ. Multiple-dose population pharmacokinetics of pyronaridine in healthy volunteers. American Journal of Tropical Medicine and Hygiene. 2008; Vol. 79 Suppl:250-99.
39. Auparakkitanon S, Chapoomram S, Kuaha K, Chirachariyavej T, Wilairat P. Targeting of hematin by the antimalarial pyronaridine. Antimicrobial Agents and Chemotherapy 2006;50(6):2197-200.
40. Basco LK, Le Bras J. In vitro activity of pyronaridine against African strains of Plasmodium falciparum. Annals of Tropical Medicine and Parasitology 1992;86(5):447-54.
41. Bloland PB. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria [WHO/HTM/RBM/2003.50]. Geneva: World Health Organization, 2003.
42. Brice BK, William Y, Lacina O, Félix Y, Hugues A, Léonardo B, et al.In vitro susceptibility of Plasmodium falciparum isolates from Abidjan, Cote d'Ivoire, to artemisinin, chloroquine, dihydroartemisinin and pyronaridine. Tanzanian Journal of Health Research 2010;12(1):73-9.
43. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. American Journal of Tropical Medicine and Hygiene 2003;68(2):133-9.
44. Chavalitshewinkoon-Petmitr P, Pongvilairat G, Auparakkitanon S, Wilairat P. Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro. Parasitology International 2000;48(4):275-80.
45. Chang C, Lin-Hua T, Jantanavivat C. Studies on a new antimalarial compound: pyronaridine. Transactions of the Royal Society of Tropical Medicine and Hygiene 1992;86(1):7-10.
46. Childs GE, Häusler B, Milhous W, Chen C, Wimonwattrawatee T, Pooyindee N, et al.In vitro activity of pyronaridine against field isolates and reference clones of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene 1988;38(1):24-9.
47. Review of pyronaridine anti-malarial properties, product characteristics. Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, et al. Malaria Journal 2010;11:270.
48. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, et al.Artemisinin resistance: current status and scenarios for containment. Nature Reviews Microbiology 2010;8(4):272-80.
49. Duparc S, Borghini-Fuhrer I, Craft CJ, Arbe-Barnes S, Miller RM, Shin CS, et al.Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malaria journal 2013;12(70):Epub 2013/02/26.
50. Fu S, Xiao SH. Pyronaridine: a new antimalarial drug. Parasitology Today 1991;7(11):310-3.
51. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
52. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians?. BMJ 2008;336(7651):995-8.
53. Higgins JPT, Green S (editors). Appendix 5b: Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 4.2.5 [updated May 2005]. The Cochrane Collaboration, 2005. Available from www.cochrane.org/resources/handbook/hbook.htm (accessed 17 June 2006).
54. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
55. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
56. Kurth F, Pongratz P, Bélard S, Mordmüller B, Kremsner PG, Ramharter M. In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malaria Journal 2009;8:79.
57. Kurtzhals JAL. Importance of the long-acting partner drug in artemisinin-based combination therapy. Expert Reviews in Pharmacology 2008;1(6):745-7.
58. Lim P, Wongsrichanalai C, Chim P, Khim N, Kim S, Chy S, et al.Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrobial Agents and Chemotherapy 2010;54(5):2135-42.
59. Chandler J, Churchill R, Higgins J, Lasserson T, Tovey D. Methodological Expectations of Cochrane Intervention Reviews (MECIR). Methodological standards for the conduct of new Cochrane Intervention Reviews. Version 2.1, 8 December 2011. Available at: http://www.editorial-unit.cochrane.org/sites/editorial-unit.cochrane.org/files/uploads/MECIR_conduct_standards%202.1.pdf (accessed on 4 November 2012).
60. Naisbitt DJ, Williams DP, O'Neill PM, Maggs JL, Willock DJ, Pirmohamed M, et al.Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs. Chemical Research in Toxicology 1998;11(12):1586-95.
61. Nosten N, White NJ. Artemisinin-based combination treatment of falciparum malaria. American Journal of Tropical Medicine and Hygiene 2007;77(Suppl 6):181-92.
62. Pradines B, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R, et al.In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. Journal of Antimicrobial Chemotherapy 1998; Vol. 42, issue 3:333-9.
63. Pradines B, Briolant S, Henry M, Oeuvray C, Baret E, Amalvict R, et al.Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum. Malaria Journal 2010;9:339.
64. Price RN, Marfurt J, Chalfein F, Kenangalem E, Piera KA, Tjitra E, et al.In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrobial Agents and Chemotherapy 2010;54(12):5146-50.
65. Qi J, Yang CZ, Wang CY, Wang SB, Yang M, Wang JH. Function and mechanism of pyronaridine: a new inhibitor of P-glycoprotein-mediated multidrug resistance. Acta Pharmacologica Sinica 2002;23(6):544-50.
66. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
67. Ringwald P, Eboumbou EC, Bickii J, Basco LK. In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum. Antimicrobial Agents and Chemotherapy 1999;43(6):1525-7.
68. Ruscoe JE, Tingle MD, O'Neill PM, Ward SA, Park BK. Effect of disposition of mannich antimalarial agents on their pharmacology and toxicity. Antimicrobial Agents and Chemotherapy 1998;42(9):2410-6.
69. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2008.
70. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007483.pub2]
71. Vivas L, Rattray L, Stewart L, Bongard E, Robinson BL, Peters W, et al.Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Tropica 2008;105(3):222-8.
72. White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitology Today 1996;12(10):399-401.
73. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al.Averting a malaria disaster. Lancet 1999;353(9168):1965-7.
74. White NJ. The assessment of antimalarial drug efficacy. Trends in Parasitology 2002;18(10):458-64.
75. White NJ. Antimalarial drug resistance. Journal of Clinical Investigation 2004;113(8):1084-92.
76. World Health Organization. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. http://whqlibdoc.who.int/publications/2008/9789241596305_eng.pdf (accessed 28 December 2010).
77. World Health Organization. Malaria treatment guidelines -2nd edition. www.who.int/malaria/publications/atoz/9789241547925/en/index.html (accessed 20 November 2010).
78. World Health Organization. Global report on antimalarial drug efficacy and drug resistance 2000-2010. www.who.int/malaria/publications/atoz/9789241500470/en/index.html (accessed 28 December 2010).
79. World Health Organization. Global plan for artemisinin resistance containment (GPARC). www.who.int/malaria/publications/atoz/9789241500838/en/index.html (accessed 4 February 2011).
80. WHO Global Malaria Programme. World Malaria Report 2012. World Malaria Report 2012. Geneva: World Health Organization, 2012.
81. Yang HL, Liu DQ, Yang YM, Huang KG, Dong Y, Yang PF, et al.In vitro sensitivity of Plasmodium falciparum to eight antimalarials in China-Myanmar and China-Lao PDR border areas. Southeast Asian Journal of Tropical Medicine and Public Health 1997;28(3):460-4.